aldara
viatris healthcare limited - imiquimod - condylomata acuminata; keratosis; keratosis, actinic; carcinoma, basal cell - antibijotiċi u kimoterapewtiċi għal użu dermatoloġiku - imiquimod cream is indicated for the topical treatment of :external genital and perianal warts (condylomata acuminata) in adults. small superficial basal cell carcinomas (sbccs) in adults. clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (aks) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.
vaniqa
almirall, s.a. - eflornithine - hirsutiżmu - preparazzjonijiet oħra dermatoloġiċi - trattament ta 'hirsutiżmu tal-wiċċ fin-nisa.
zyclara
viatris healthcare limited - imiquimod - keratosis; keratosis, actinic - antibijotiċi u kimoterapewtiċi għal użu dermatoloġiku - zyclara huwa indikat għall-trattament topiku ta klinikament tipiku, mhux hyperkeratotic, mhux hypertrophic, viżibbli jew palpable keratosis actinic tal-wiċċ sħiħ jew scalp balding fl-adulti immunokompetenti meta huma għażliet oħra ta ' trattament topiku contraindicated jew inqas xierqa.
opzelura
incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - preparazzjonijiet oħra dermatoloġiċi - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
xalkori
pfizer europe ma eeig - crizotinib - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.
adcetris
takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - aġenti antineoplastiċi - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris huwa indikat għall-kura ta 'pazjenti adulti b'all rikadut jew refrattarju cd30+ ta' hodgkin il-limfoma (hl):wara asct, orfollowing mill-inqas żewġ terapiji ta 'qabel meta asct jew multi-aġent tal-kimoterapija mhux għażla ta' trattament. sistemiċi astroċitoma l-kbira taċ-ċelluli lymphomaadcetris f'kumbinazzjoni ma ' cyclophosphamide, doxorubicin u prednisone (chp) huwa indikat għall-pazjenti adulti li ma ġietx ikkurata qabel sistemika astroċitoma l-kbira taċ-ċelluli tal-limfoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.
stocrin
merck sharp & dohme b.v. - efavirenz - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - stocrin huwa indikat fit-trattament ta 'kombinazzjoni antivirali ta' adulti, adolexxenti u tfal ta 'tlett snin u aktar b'infezzjoni ta' hiv-1 tal-bniedem-immunodefiċjenza-virus-1. stocrin ma ġiex studjat biżżejjed fil-pazjenti f'fażi avvanzata tal-marda tal-hiv, u speċifikament pazjenti b'għadd cd4 < 50 ċellula/mm3, jew wara falliment ta ' protease inhibitor (pi) taħt kuri li kien fihom. għalkemm il-reżistenza msallba ta 'efavirenz ma' pis ma ġietx dokumentata, fil-preżent hemm biżżejjed informazzjoni fuq l-effikaċja tal-użu sussegwenti tal-pi tal-kura kombinata bbażata fuq wara li jkunu fallew il-kuri li fihom stocrin.
pedea
recordati rare diseases - ibuprofen - ductus arteriosus, privattiva - terapija kardijaka - trattament ta 'ductus arteriosus ta' brevett emodinamikament sinifikanti fit-trabi tat-twelid li twieldu qabel iż-żmien inqas minn 34 ġimgħa ta 'età tal-ġestazzjoni.
insulin human winthrop
sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - drogi użati fid-dijabete - dijabete mellitus fejn huwa meħtieġ it-trattament bl-insulina. insulina bniedem winthrop mgħaġġla huwa wkoll adattat għat-trattament ta ' koma hyperglycaemic u ketoacidosis, kif ukoll għall-kisba minn qabel, intra - u postoperative stabbilizzazzjoni fil-pazjenti bl-diabetes mellitus.
insuman
sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - drogi użati fid-dijabete - dijabete mellitus fejn huwa meħtieġ it-trattament bl-insulina. insuman rapid huwa wkoll adattat għall-kura ta 'koma ipergliċemika u ketoaċidożi, kif ukoll għall-kisba ta' stabilizzazzjoni minn qabel, intra u wara l-operazzjoni f'pazjenti bid-dijabete mellitus.